| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b210a364a6fa8bb4d58325a6ed16a499
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcae8bed7f51e3f16a880db626620cba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ffb582b846ffe92cb35114c104f518d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25b37a100f3ebcfd8868a412dd7ad7c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_430f348c64b6567977b4f205908ba6b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2aab8a193e5f18a1c059c246d24e06e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 |
| filingDate |
2007-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef43e8eb603bcc9a57bb10d7d9d66788
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_caa4b36e3979c72c3801d7fe1616a1ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07972fabb91f2988bf9cd5318da35a6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19e865dc276b5a67c189a78090b6d501
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eef7ff9f1605f300caee1d8bbd24765f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3acd6feeab3214d71b9a361d8ccf4253 |
| publicationDate |
2009-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009202506-A1 |
| titleOfInvention |
Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| abstract |
Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo. |
| priorityDate |
2001-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |